[2]
Yokomizo T, Nakamura M, Shimizu T. Leukotriene receptors as potential therapeutic targets. J Clin Invest 2018; 128(7): 2691-701.
[11]
Zaitsu M, Hamasaki Y, Yamamoto S, Kita M, Hayasaki R, Muro E, et al. Effect of dexamethasone on leukotriene synthesis in DMSO-stimulated HL-60 cell. Prostaglandins Leukot Essent Fatty Acids 1998; 59(6): 385-93.
[18]
Jua EM, Leea SE, Hwangb HJ, Kima JH. Antioxidant and anticancer activity of extract from Betula platyphylla var. japonica. Life Sci 2004; 74(8): 1013-26.
[24]
Soni KK, Raut N, Lawal TO, Patel U, Mahady GB. A purified fraction of Ocimum tenuiflorum (L.) inhibits LTC4, LTA4 and COX-2 activities, down-regulates mRNA expression in HL-60 cells and reduces lung inflammation in an OVA induced asthma model in BALB/c mice. Immunol Endocr Metab Agents Med Chem 2017; (17): 115-26.
[26]
Shah BN, Patel NP, Pandya P. Role of leukotriene in inflammation and anti-leukotriene therapy. J Pharm Res 2008; 1(2): 113-25.
[28]
Soni KK, Patel U, Artwolt J, Nunamaker E, Mahady GB. Reduction of OVA-induced lung inflammation in mice treated with Ayurvedic herbs using 2-D and 3-D imaging. Pharm Biol 2012; 50: 564.
[29]
Soni KK, Shrivastava PN, Jones T, Mahady JL, Patel U, Mukherjee P, et al. Extracts of Bacopa monnieri (L) Pennell down-regulate the expression of leukotriene C4 synthase mRNA in HL-60 cells and suppress OVA induced inflammation in BALB/c Mice. Curr Bioact Compd 2014. 10: 021-30.
[35]
Jain B, Jain VK, Ahirwar D, Ahirwar B. Acute oral toxicity and in vitro leukotriene inhibitory property of hydro-alcoholic extract of Nicotiana tabacum in guinea pig Lung strips. Int J Green Pharm 2018; 12(2): 107-14.
[37]
Guimaraes JP, Filgueiras LR, Martins JO, Jancar S. Leukotriene involvement in the insulin receptor pathway and macrophage profiles in muscles from type 1 diabetic mice. Mediat Inflamm 2019; p. 4596127.
[42]
Lee DK, Robb FM, Sims EJ, Currie GP, McFarlane LC, Lipworth BJ. Systemic bioactivity of intranasal triamcinolone and mometosone in perennial allergic rhinitis 2003. 55: 310-13.
[43]
Joseph GA, Yuan G, Cheuk KL. Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis. US4663347 (1987).
[44]
Edwin SW, Alexander K. Synthetic flavonoidsas inhibitors of leukotrienes and 5-lpoxygenase. US4889941 (1989).
[45]
Daines RA, Kingsbury WD, Pendrak I. Benzoic acid derivatives for treating leukotrienerelated diseases. WO9118880 (1991).
[46]
Zamboni R, Guay D, Labelle M. Quinoline derivatives as leukotriene ntagonists. WO1993021159 (1993).
[47]
Brooks DW, Woods KW, Rodrigues KE. Indole carboxylate derivatives which inhibits leukotriene biosynthesis. WO9412179 (1994).
[48]
Cohen N. Substituted pyridine leukotriene B4 antagonists.AU690258 (1995).
[49]
Norbert D, Wolfram H, Labaudiniere R. Substituted quinolyl exhibiting selective compound leukotriene B4 antagonist activity.S5492915 (1996).
[50]
Gareau Y, Labelle M, Dufresne C, et al. Heteroaryl diol acid as leukotriene antagonists. WO9640638 , (1996).
[51]
Fleisch JH, Jackson WT, Sawyer JS. Leukotriene antagonists useful for treating ischemia reperfusion injury. WO9842346 (1998).
[52]
Makovec F, Peris W, Rovati LC. Tyrosine derivatives with antileukotriene activity. WO2001058892 (2001).
[53]
Rubin PD. Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors. US6509353 (2003).
[54]
Liversidge G, Jenkins S, Wertz C, Bosch H. Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations. WO2006099591 (2006).
[55]
Maus J, Fyrnys B, Hoffmann T, et al. The combination of anti-cholinergic and leukotriene receptor antagonists for the treatment of respiratory diseases. WO2006097250 (2006).
[56]
Arnaiz D, Davey D, Guilford W, et al. Di-amine derivatives as inhibitors of leukotriene A4 hydrolase. WO2007079078 (2007).
[57]
Armstrong HM, Change LL, Chu L, Sisco RM. OK, H.O., Xu, J., Ujjainwalla, F. Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis. US20090258885 In: (2009).
[58]
Armstrong M, Reisdorph NAM, Rabinovitch N. Measurement and analysis of leukotrienes. WO2010045633 (2010).
[59]
Gosselin F, Vydra V. Compounds and methods for leukotriene biosynthesis inhibition. US7915298 (2011).
[60]
Dominique R, Goodnow RA, Kowalczyk A, Qiao JLQ, Sidduri A, Tilley JW. Leukotriene B4 inhibitors. US8093253 (2012).
[61]
Berry A, Chen Z, Lombaert SD, et al. Biarylamide inhibitors of leukotriene production. WO201208281 (2012).
[62]
Kim JH, Cho AC, Kim GY, et al. Use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancer. US8288357 (2012).
[63]
Rathod R, Bhatt T, Joshi K, Dole B, Murty-Kadiyala VNS, Thennati R. Cysteinyl leukotriene antagonists. WO2013051024 (2013).
[64]
Taub R, Bortz T, Franc J, et al. Phenylalkyl n-hydroxyurea for treating leukotriene related pathologies. US20130190514 (2013).
[65]
Kim JH, Choi JA, Kim EY, et al. Method of treating cancer with antibodies against long-form leukotriene B4 receptor BLT2. US8518889 (2014).
[66]
Bylock LA. Benzodioxanes in combination with other actives for inhibiting leukotriene production. WO2013131901 (2014).
[67]
Bartolozzi A, Bosanac T, Chen Z, et al. Oxadiazole inhibitors of leukotriene production. US8658661 (2014).
[68]
Lombart SD, Liu W, Lo HY, Nemoto PA. Benzimidazole inhibitors of leukotriene production. US8772304 (2014).
[69]
Wojciak JM, Dickerson CT, Visentin DB, Sabbadini RA. Compositions and methods for binding Cysteinyl Leukotrienes (CysLTs) for treatment of disease. US20150152172 (2015).
[70]
Rubinstein M, Dvash-Riesefeild E. Inhibitors of leukotriene mediated activity for alleviating chemotherapy side effects and stress induced cell death. WO2015125137 (2015).
[71]
Heim-Riether A, Padyana AK, Liang S, Taylor SJ, Zhang Q. Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase. US9139567 (2015).
[72]
Stack DR. Leukotriene B4 antagonist compound. US9187411 (2015).
[73]
Nicolls MR, Tian W, Rajadas J. Treatment of pulmonary hypertension with Leukotrienes inhibitors. US2013025178 (2013).
[74]
Maus J, Fyrnys B, Hofmann T, Weingart M, Szelenyl I. The combination of anticholinergic and leukotriene receptor antagonists for the treatment of respiratory diseases. EP1863476 (2016).
[75]
Abeywardane A, Brunette SR, Burke MJ, et al. Inhibitors of leukotriene production. US9403830 (2016).
[76]
Gosselin J, Gaudreault E. Use of leukotriene B4 in combination with a toll-like receptor legend, a rig-i-like receptor legend, or a nodlike receptor legend to enhance the innate immune response.US20170151204 (2017).
[77]
Kim JH. Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. US9772324 (2017).
[78]
Rubinstein M, Dvash-Riesefeild E. Inhibitors of leukotrienemediated activity for treating side Orengo, effects of statin therapy.US20180064682 (2018).
[79]
Orengo JM, Allinne J, Murphy AJ, Yancopoulo GD. Methods of treating inflammatory conditions. WO2018102597 (2018).
[80]
Roinestad K, Guilford W, Kirkland T, Bhatt L, Springman E. Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase. WO2018107158 (2018).
[81]
George JT, Emiola A. Leukotriene receptor antagonists and their derivatives for use as antibacterial agents. US20180185332 (2018).
[82]
Rockson SG, Nicolls MR, Tian WA, Jiang X, Kim J. LTB4 inhibition to prevent and treat human lymphedema. US20180193296 (2018).
[83]
Benison J. Reduction of pro-inflammatory HDL using a leukotriene inhibitor. WO2018152405 (2019)
[84]
Bresnick SD. Prophylactic leukotriene inhibitor and implant displacement therapy for prevention and treatment of capsular contracture in silicone breast augmentation. US10179129 (2019).
[85]
May BC. Use of levocetirizine and montelukast in the treatment of autoimmune disorders. US10201537 (2019).
[86]
Choi Y, Kim JH, Lee K, et al. Novel compound having BLT inhibitory activity and composition,for preventing or treating inflammatory diseases, comprising same as active ingredient. US20190071395
[87]
Paiement N, Zerbe HG, Conway JW, Obeid R, Aigner L, Michael J. Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists. US20190133925 (2019).
[88]
Roinestad K, Guilford W, Kirkland T, Bhatt L, Springman EB. Pendant amines and derivatives as inhibitors of leukotriene A4 hydrolase. US20190161437 (2019).
[89]
Amin N, Graham N, Pirozzi G, Teper A. Methods for treating or preventing asthma by administering an IL-4R antagonist.US20190169299 (2019).
[90]
Lai Y. Cyclopropyl unsaturated quinoline compound used as leukotriene receptor antagonist and applications thereof. US10315997 (2019)
[91]
Springman EB, Pugh MM, Bhatt L, Grosswald R. Methods of inhibiting leukotriene A4 hydrolase. US10350197 (2019).
[92]
Sai L, Yanqiu Z, Dongmei C, Yinjun L. Effect of rosuvastatin and benazepril on matrix metalloproteinase-2, matrix metalloproteinase-9 and leukotriene B4 of patients with acute myocardial infarction. Trop J Pharm Res 2019; 18(3): 625-30.